15.36
+0.58(+3.92%)
Currency In USD
| Previous Close | 14.78 |
| Open | 14.63 |
| Day High | 15.49 |
| Day Low | 14.61 |
| 52-Week High | 20.9 |
| 52-Week Low | 7 |
| Volume | 48,269 |
| Average Volume | 109,716 |
| Market Cap | 317.69M |
| PE | -3.66 |
| EPS | -4.2 |
| Moving Average 50 Days | 15.1 |
| Moving Average 200 Days | 14.5 |
| Change | 0.58 |
If you invested $1000 in Amarin Corporation plc (AMRN) 10 years ago, it would be worth $508.61 as of January 20, 2026 at a share price of $15.36. Whereas If you bought $1000 worth of Amarin Corporation plc (AMRN) shares 5 years ago, it would be worth $123.87 as of January 20, 2026 at a share price of $15.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
GlobeNewswire Inc.
Jan 09, 2026 12:00 PM GMT
DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with el
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
U.S. IPE Market Leadership Sustained; $70M Restructuring OPEX Savings on Pace for Mid-2026; Completed Transition to Fully Partnered Model Across All International MarketsDUBLIN and BRIDGEWATER, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Amarin Corpora
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
GlobeNewswire Inc.
Nov 09, 2025 9:15 PM GMT
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinf